Highly sensitive immunoassay for human cardiac troponin based
on photon-upconversion nanoparticles

a 2021

Highly sensitive immunoassay for human cardiac troponin based on photon-upconversion nanoparticles

BRANDMEIER, Julian, Kirsti RAIKO, Zdeněk FARKA, Riikka PELTOMAA, Matthias Jürgen MICKERT et. al.

Základní údaje

Originální název

Highly sensitive immunoassay for human cardiac troponin based on photon-upconversion nanoparticles

Autoři

BRANDMEIER, Julian, Kirsti RAIKO, Zdeněk FARKA, Riikka PELTOMAA, Matthias Jürgen MICKERT, Antonín HLAVÁČEK, Petr SKLÁDAL, Tero SOUKKA a Hans-Heiner GORRIS

Vydání

UPCONline 2021, 2021

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

10406 Analytical chemistry

Stát vydavatele

Francie

Utajení

není předmětem státního či obchodního tajemství

Organizační jednotka

Přírodovědecká fakulta

Příznaky

Mezinárodní význam

Změněno: 10. 5. 2021 22:48, doc. Mgr. Zdeněk Farka, Ph.D.

Anotace

V originále

With 15.2 million deaths in 2016 and a rising trend, more people die annually suffering a heart attack than from any other cause or disease. There is only a limited time available from the onset of the symptoms of acute myocardial infarction (AMI) to lifesaving treatment. Cardiac troponin is the recommended marker in the early AMI diagnosis. The standard assays are based on electrochemiluminescence, chemiluminescence, or electrochemical detection. Even though reaching acceptable limits of detection (LOD), higher sensitivity is still necessary. To overcome the performance of current methods, we designed streptavidin-modified photon upconversion nanoparticles (SA-UCNP) based on a PEG linker and utilized them in upconversion immunoassays to detect cardiac troponin. We developed two assays; a microtiter plate-based upconversion immunoassay (ULISA) for sensitive laboratory diagnosis and a lateral-flow immunoassay (LFIA) for rapid detection. The PEG linker allowed reducing the non-specific interactions due to the steric hindrance and repulsion effects. For the ULISA, we chose a 2+2 assay configuration, with two monoclonal antibodies coated on the surface to capture the analyte, which was then detected by two biotinylated antibodies and SA-UCNPs. The LFIA was based on a 2+1 configuration, with one biotinylated antibody for the detection; biotinylated BSA was used for the control line. We achieved LOD of 4.7 pg/mL for the ULISA and 13.8 ng/mL for LFIA, respectively. Furthermore, we demonstrated that the ULISA is a feasible alternative to existing assays, with LOD in the serum of 15.5 pg/mL, two times lower than the troponin concentration in healthy patients.

Návaznosti

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

LTAB19011, projekt VaV

Název: Luminiscenční imunostanovení jako citlivý nástroj pro diagnostiku nemocí včel

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Luminiscenční imunostanovení jako citlivý nástroj pro diagnostiku nemocí včel, INTER-ACTION

Citovat

BRANDMEIER, Julian, Kirsti RAIKO, Zdeněk FARKA, Riikka PELTOMAA, Matthias Jürgen MICKERT, Antonín HLAVÁČEK, Petr SKLÁDAL, Tero SOUKKA a Hans-Heiner GORRIS. Highly sensitive immunoassay for human cardiac troponin based on photon-upconversion nanoparticles. In UPCONline 2021. 2021.

@proceedings{1757239,
   author = {Brandmeier, Julian and Raiko, Kirsti and Farka, Zdeněk and Peltomaa, Riikka and Mickert, Matthias Jürgen and Hlaváček, Antonín and Skládal, Petr and Soukka, Tero and Gorris, HansandHeiner},
   booktitle = {UPCONline 2021},
   language = {eng},
   title = {Highly sensitive immunoassay for human cardiac troponin based on photon-upconversion nanoparticles},
   year = {2021}
}

TY  - CONF
ID  - 1757239
AU  - Brandmeier, Julian - Raiko, Kirsti - Farka, Zdeněk - Peltomaa, Riikka - Mickert, Matthias Jürgen - Hlaváček, Antonín - Skládal, Petr - Soukka, Tero - Gorris, Hans-Heiner
PY  - 2021
TI  - Highly sensitive immunoassay for human cardiac troponin based on photon-upconversion nanoparticles
N2  - With 15.2 million deaths in 2016 and a rising trend, more people die annually suffering a heart attack than from any other cause or disease. There is only a limited time available from the onset of the symptoms of acute myocardial infarction (AMI) to lifesaving treatment. Cardiac troponin is the recommended marker in the early AMI diagnosis. The standard assays are based on electrochemiluminescence, chemiluminescence, or electrochemical detection. Even though reaching acceptable limits of detection (LOD), higher sensitivity is still necessary. To overcome the performance of current methods, we designed streptavidin-modified photon upconversion nanoparticles (SA-UCNP) based on a PEG linker and utilized them in upconversion immunoassays to detect cardiac troponin. We developed two assays; a microtiter plate-based upconversion immunoassay (ULISA) for sensitive laboratory diagnosis and a lateral-flow immunoassay (LFIA) for rapid detection. The PEG linker allowed reducing the non-specific interactions due to the steric hindrance and repulsion effects. For the ULISA, we chose a 2+2 assay configuration, with two monoclonal antibodies coated on the surface to capture the analyte, which was then detected by two biotinylated antibodies and SA-UCNPs. The LFIA was based on a 2+1 configuration, with one biotinylated antibody for the detection; biotinylated BSA was used for the control line. We achieved LOD of 4.7 pg/mL for the ULISA and 13.8 ng/mL for LFIA, respectively. Furthermore, we demonstrated that the ULISA is a feasible alternative to existing assays, with LOD in the serum of 15.5 pg/mL, two times lower than the troponin concentration in healthy patients.
ER  -

Podrobný výpis o publikaci